Screening 584 Natural Compounds to Find Ones That Boost the Body's Own Antimicrobial Peptide Production

Researchers constructed a stable macrophage cell line expressing a luciferase reporter driven by a 2-kb AvBD9 gene promoter using lentiviral transduction and puromycin selection. This reporter line was used for high-throughput screening of 584 natural products, with hits defined as compounds achieving a Z-score ≥ 2.0. Validated hits underwent secondary screening in chicken HTC macrophages and jejunal explants for dose-dependent defensin induction. The lead compound wortmannin was tested in vivo via oral administration to chickens, measuring defensin gene expression in gut tissue. Synergy experiments combined wortmannin with butyrate, and antibacterial activity was assessed using chicken monocyte killing assays.

Antibiotic resistance is one of the greatest threats to global health, and poultry production is a major contributor to antibiotic overuse. Rather than developing new antibiotics that bacteria can evolve resistance to, this approach boosts the animal's own immune defense peptides — a strategy that is inherently harder for bacteria to evade because defensins attack through multiple mechanisms simultaneously. If this approach translates to practice, it could reduce antibiotic use in agriculture while maintaining animal health.

This study exemplifies the 'host-directed therapy' paradigm — instead of directly killing pathogens, you enhance the host's own immune defenses. Antimicrobial peptides like defensins are ancient immune weapons that have remained effective for hundreds of millions of years of evolution because they attack bacteria through multiple mechanisms, making resistance development extremely difficult. Finding natural compounds that stimulate defensin production could transform not only animal agriculture but potentially human medicine as well.

The study was conducted primarily in chicken systems (macrophage cell lines, gut explants, and live chickens), and results may not directly translate to human defensin biology. Wortmannin is a known PI3K inhibitor with multiple cellular effects, which could cause unintended side effects at therapeutic doses. The in vivo validation used oral administration but did not assess disease protection outcomes or safety in long-term feeding trials. The screen focused on defensin induction and did not evaluate whether the induced peptides effectively prevented actual infections in treated animals.